Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JW Theriac undisclosed SGLT1 SGLT2 dual inhibitor
- Development stage
- Preclinical
- Lead developer
- JW Pharmaceutical
- Modality
- Small Molecules
01
Overview
An undisclosed **small-molecule dual inhibitor of sodium-glucose cotransporter 1 and sodium-glucose cotransporter 2** being developed by **JW Theriac Pharmaceuticals** for **cardiovascular system and metabolic diseases**. Based on the company pipeline description, the program is in **preclinical development**. No public non-code compound name, brand name, formulation details, or specific lead indication were identified from the provided materials, so this asset is best characterized as an unnamed preclinical dual SGLT1/SGLT2 inhibitor intended to modulate glucose handling and related cardiometabolic biology.
- Other names
- JW Theriac Pharmaceuticals-SGLT1-SGLT2-small molecule-Cardiovascular system and metabolic diseases
02
Targets
SLC5A1 (Sodium Glucose Cotransporter 1)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on JW Theriac undisclosed SGLT1 SGLT2 dual inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JW Theriac undisclosed SGLT1 SGLT2 dual inhibitor.